Dexmedetomidine hydrochloride (Precedex) is a potent, selective, orally active α2-adrenoceptor agonist with a Ki value of 1.08 nM. It shows 1620-fold selectivity over α1-adrenoceptors. Dexmedetomidine hydrochloride (Precedex) can protect against sepsis-induced acute lung injury through anti-inflammatory, anti-oxidative, and anti-apoptotic effects.

α2-adrenoceptor:1.08 nM (IC50)

方法：NR8383 肺泡巨噬细胞用 10μg/ml LPS 刺激 24 小时后， 用Dexmedetomidine hydrochloride (Precedex) （0.01，0.1，1，10 ，50 μM，2小时）再处理2小时，CCK-8 测定评估不同浓度的 Dexmedetomidine hydrochloride (Precedex) 预处理对 LPS 处理的 NR8383 细胞活力的影响。
结果：细胞活力随着Dexmedetomidine hydrochloride (Precedex) 浓度增加而逐渐增加。[1]

方法：使用暴露于LPS的 C57BL/6J 小鼠，先给予 Dexmedetomidine hydrochloride (Precedex)（50μg/kg，腹膜内注射），研究了其是否通过在体内通过 HIF-1a/HO-1 通路调节线粒体动力学过程来提供肺保护。
结果：Dexmedetomidine hydrochloride (Precedex)减轻了肺病理损伤，降低了氧化应激指数 （OSI），改善了线粒体功能障碍，上调了 HIF-1α 和 HO-1 的表达，并伴有线粒体的动态过程转变为融合。[1]

In vitro HDAC assay:HDAC activity is analyzed by using an HDAC assay kit. This assay is based on the ability of DU-145 nuclear extract, which is rich in HDAC activity, to mediate the deacetylation of the biotinylated [3H]-acetyl histone H4 peptide that is bound to streptavidin agarose beads. The release of [3H]-acetate into the supernatant is measured to calculate the HDAC activity. Sodium butyrate (0.25-1 mM) is used as a positive control.